| Name | Title | Contact Details |
|---|
Updates, earnings and commercializationListen to the audio recording of our recent shareholder call where we discussed the latest updates, gave an overview of our earnings report and highlighted the commercialization efforts underway at Predictive Onco...
Staffed by industry experts, Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech`s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Manufacturing—including development, Compliance, Regulatory, and Validation. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area. Our Culture: At Pharmatech Associates, our mission is to fulfill customer expectations throughout the development and execution of tailored, high value, innovation solutions. We are committed to fostering an environment that is professional and forth right. These principles are captured in the values we believe are essential to maintaining our supportive culture and our commitment to our clients` success. We seek to establish an atmosphere of openness, objectivity, accountability, mutual respect and teamwork so each employee can realize their fullest potential for personal and professional growth. We value work life balance. At Pharmatech talent matters, and we tackle each project with a “no fear” attitude. We stand together as a team, and we`ve got your back. Pharmatech`s commitment to integrity is unwavering.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.
Baxter Pharmaceutical Products is a New Providence, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
University Cancer & Blood Center’s highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the...